Related Experiment Video

Updated: Sep 20, 2025

Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis
09:42

Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis

Published on: June 26, 2019

8.9K

Resistance Mechanisms of the Metastatic Tumor Microenvironment to Anti-Angiogenic Therapy

Lars M Schiffmann1, Christiane J Bruns1, Thomas Schmidt1

  • 1Department of General, Visceral, Cancer and Transplantation Surgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Frontiers in Oncology
|June 6, 2022
PubMed

Insights

Anti-angiogenic therapies show promise but face resistance in cancer treatment. Understanding tumor resistance mechanisms, especially at metastatic sites, is crucial for improving patient outcomes.

Area of Science:

  • Oncology
  • Vascular Biology

Background:

  • Angiogenesis, the formation of new blood vessels, is a target for cancer therapy.
  • Anti-angiogenic drugs are standard care but often face limited efficacy due to resistance.
  • Tumor resistance mechanisms, similar to chemotherapy resistance, hinder treatment success.

Purpose of the Study:

  • To review current knowledge on mechanisms of resistance to anti-angiogenic therapies.
  • To focus on resistance at the metastatic tumor site.
  • To discuss the translational and clinical relevance of understanding resistance.

Main Methods:

  • Literature review of preclinical and clinical studies on anti-angiogenic therapy resistance.
  • Analysis of tumor cell and microenvironmental factors contributing to resistance.
  • Synthesis of current knowledge on resistance mechanisms.

Main Results:

  • Tumors develop resistance to anti-angiogenic drugs through various cellular and microenvironmental adaptations.
  • Resistance mechanisms are observed both in preclinical models and in clinical settings.
  • Understanding these mechanisms is key to overcoming therapeutic limitations.

Conclusions:

  • Further research into tumor resistance mechanisms is essential for improving anti-angiogenic therapy efficacy.
  • Targeting resistance pathways, particularly at metastatic sites, holds therapeutic potential.
  • Translational and clinical insights are needed to develop more effective anti-cancer strategies.
Keywords:
angiogenesisanti-angiogenic therapymetastatic microenvironmentresistancetumor microenvironment

More Related Videos

Isolation and Culture Expansion of Tumor-specific Endothelial Cells10:15

Isolation and Culture Expansion of Tumor-specific Endothelial Cells

Published on: October 14, 2015

11.3K
Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

9.9K

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K